113.08
1.56%
1.74
Biontech Se Adr stock is traded at $113.08, with a volume of 863.98K.
It is up +1.56% in the last 24 hours and up +10.71% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$111.34
Open:
$110.76
24h Volume:
863.98K
Relative Volume:
1.05
Market Cap:
$27.11B
Revenue:
$3.30B
Net Income/Loss:
$-501.07M
P/E Ratio:
9.8003
EPS:
11.5384
Net Cash Flow:
$1.03B
1W Performance:
-6.06%
1M Performance:
+10.71%
6M Performance:
+31.67%
1Y Performance:
+10.00%
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-11-24 | Initiated | Wells Fargo | Overweight |
Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
Nov-19-24 | Initiated | Berenberg | Buy |
Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
May-14-24 | Initiated | Evercore ISI | In-line |
Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
Jan-05-24 | Initiated | Oppenheimer | Perform |
Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-17-23 | Upgrade | Redburn | Neutral → Buy |
Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
Aug-17-22 | Initiated | Cowen | Market Perform |
Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-22-21 | Initiated | Deutsche Bank | Hold |
Oct-07-21 | Initiated | Jefferies | Hold |
Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
May-18-21 | Initiated | Goldman | Neutral |
May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-03-20 | Resumed | Berenberg | Buy |
Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-22-20 | Downgrade | UBS | Buy → Neutral |
Nov-05-19 | Initiated | Wolfe Research | Outperform |
Nov-04-19 | Initiated | Berenberg | Buy |
Nov-04-19 | Initiated | BofA/Merrill | Buy |
Nov-04-19 | Initiated | Canaccord Genuity | Buy |
Nov-04-19 | Initiated | JP Morgan | Overweight |
Nov-04-19 | Initiated | SVB Leerink | Outperform |
Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech SE ADR falls Thursday, underperforms market - MarketWatch
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
3 No-Brainer Biotech Stocks to Buy With $200 Right Now - The Motley Fool
Stocks Generating Improved Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock faces oncology pipeline test - Investing.com
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock balances COVID legacy, oncology future - Investing.com
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily
BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech's SWOT analysis: oncology pipeline fuels stock's potential amid market volatility - Investing.com
BioNTech Stock Got A IBD RS Rating Lift - MSN
BioNTech ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Inkl
Analysts Turn Bullish on BioNTech Stock Amid Volatility - Schaeffers Research
10 Biggest Biotechnology Companies - Investopedia
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up - Yahoo Finance
Stock Futures Quiet as Market Heads for Winning Week - Schaeffers Research
BioNTech Earnings: Strong Covid Revenue, but Full-Year Expectations Unchanged - Morningstar
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
Weekly Upgrades and Downgrades - InvestorPlace
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase - Yahoo Finance
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):